卵巢癌的生物治疗研究进展
|
摘要
卵巢癌作为妇女死亡的重要因素,一直受到人们的关注。手术和化学治疗都不能达到今人满意的效果。近年随着基础科学研究的不断进展,卵巢癌生物治疗研究成为热点,有的已进入临床实验阶段,且取得了一些显著的进展。卵巢癌生物治疗包括基因治疗及免疫治疗。
It is always concered that ovarian cancer is one of important causes of women mortality.Surgery and chemotherapy can not make a satified result.Continuing advances in research of elementary science in recent years,biotherapies for Ovarian cancer have been maked hot points. Some of these have been enterd clinical experient stages and have maked a lot of notable progressions. biotherapies for Ovarian cancer include gene therapy and immunotherapy.
It is always concered that ovarian cancer is one of important causes of women mortality.Surgery and chemotherapy can not make a satified result.Continuing advances in research of elementary science in recent years,biotherapies for Ovarian cancer have been maked hot points. Some of these have been enterd clinical experient stages and have maked a lot of notable progressions. biotherapies for Ovarian cancer include gene therapy and immunotherapy.
引文
1 Kramm CM,Niehues T,Rainov NG,et al..Experimental strategies for combined suicide and immune cancer gene therapy. Anoverview. MethodsMol Biol, 2003, 215 : 137
2 Deshane J,Cabrera G,Grim J,etal.Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single chain antibody. Gynecol Oncol, 1995, 59 : 8~12
3 Al-Hendy A,Magliocco AM,Al-Tweigeri T,et al. Ovarian cancer gene therapy:repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. Am J Obstet Gynecol, 2000, 2(5) : 524~528
4 Kong B,Wang W,Liu C,et al. Efficacy of lentivirus- mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer. In Vivo, 2003, 17(2) : 153~156
5 Lu S, Wang X, Xiao L,et al. Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter. 2007, 6(3) : 397~404
6 Kigawa J , Terakawa N. Adenovirus-mediated transfer of a p53 gene in ovarian cancer. Adv Exp MedBiol, 2000, 465: 207~209
7 Song K, Cowan K H, Sinha B K. In vivo studies ofadenovirus-mediated p53 gene therapy for cisplatinum- resistant human ovarian tumor xenografts. Oncol Res, 1999, 11(3) : 153~ 156
8 Nielsen LL.Combination therapy with SCH58500(p53 adenovirus)and cyclophosphamide in predinical cancer models. Oncol Rep, 2000, 7(6) : 1191~1196
9 Buller RE,Shahin MS,Horowitz JA,et al.Long term follow-up of patints with recurrent ovarian cancer after Ad p53 gene replacement with SCH58500. Cancer Gene Ther, 2002, 9(7): 567~572
10 Yumi knegae1 Miho makimura and Izumu satio1 Asimple and efficient method for purfication of infections recombinant adenovirus. JPnJ Med Scibiol , 1994, 47 : 1571~1573
11 Vorburger SA ,Hunt KK1 Adenoviral gene therapy Oncol- ogist , 2002 ,1 :461
12 曹信杰,张颖,李会兰,等.重组人p53腺病毒注射液联合化疗治疗恶性体腔积液的疗效观察。中国药房, 2005, 23(16) : 1809~1810
13 Waston JM , Berek JS, M aza OM. Grow th inh ibition of ovarian cells induced by antisense IL-6 Oligonucleo tides. Gynecol Oncol, 1993, 49: 8
14 阮菲,解先宽,刘少阳,等. Survivin反义寡核苷酸对卵巢癌耐药细胞COC1/DDP抑制作用的实验研究。《癌症》, 2004, 23(8) : 896~899
15 Qian HN,L iu GZ, Cao SJ , et al. The experimental study ofovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes. Int J Gynecol Cancer, 2002, 12(1) : 80 ~ 85
16 Sterman DH,Gillespie CT,Carroll RG,et al. Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nat Clin Pract Oncol, 2006, 3(11) : 633~639
17 Sanches R ,Kuiper M,Penault-Llorca F,et al.Antitomoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer. implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy .Cancer Gene Ther, 2000, 7(5) : 707~720
18 Han X, Wilbanks GD, Devaja O, et al. IL-2 enhances- standard IFNgamma /LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy. Gynecol Oncol, 1999, 75 (2) : 198~ 210
19 Gyorffy S ,Palmer K,Pldor TJ , et al . Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL12. Immunol, 2001, 166(10) : 6212~6217
20 Mauceri H ,Seetharam S ,Beckett M, et al . Tumor produc- tion of angiostatin is enhanced after exposure to TNF-α. Int Cancer, 2002, 97(4) : 410~415
21 包大士等重组腺病毒载体介导血管抑素基因治疗大鼠脑胶质瘤的实验研究。中华神经科杂志, 2001, 17 (6) : 3670~3701
22 Brossart P , Wirt hs S , Stuhler G, et al. Induction of cytoto- xic T-lymphocyte responses in vivo after vaccinations with peptide pulsed dendritic cells. Blood , 2000, 96 : 3102~3108
23 Hernando JJ , Park TW, Kubler K, et al. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanc- ed gynaecological malignancies:clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother , 2002 , 51 : 45~52
24 Santin AD , Hermonat PL , Ravaggi A , et al . In vitro induction of tumor-specific human lymphocyte antigen class I rest rictedCD8 cytotoxic T lymphocytes by ovarian tumor antigen pulsed autologous dendritic cell s f rom patient swith advanced ovarian cancer . Am J Obstet Gynecol , 2000, 183 : 601~609
25 崔恒, 昌晓红, 冯捷, 等. 卵巢癌抗独特型单链抗体的人源化—抗独特型微抗体的构建与表达。中国生物化学与分子生物学报, 2002 , 18 : 490~494
26 Yang WL, Jie F , Chang XH, et al. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells. Gynecol Oncol, 2007,105 : 238~243
27 康玉,徐从剑,刘惜时,等. DC融合瘤苗治疗大鼠腹腔播散性卵巢癌。现代妇产科进展, 2005, 4(14) : 266~269
28 李芳,朱怀仕,贾平,等. 卵巢癌患者自体肿瘤细胞疫苗的临床应用。中华妇产科学杂志, 2004,1(39) : 51~52
29 Chen J , Cao ZY, Zhang P , et al. Study on the TIL and NKof IL-2 injected via pelvic retroperitoneal space in gynec- ological cancer patient. SiChuan University Transaction, 2004 , 35(3) : 406 ~408
30 Douglas D,Robert P, Catherine R,et al.Modulation of clinical reponse to IL-2 therapy in ovarian cancer patient.Gynecol Oncol , 2004, 94 : 54~60
31 王玉玲.TIL细胞联合IL-2腹腔注射治疗卵巢癌腹水12 例。山东医药,2002 ,42 (24) : 14
32 Zhang XY, Jie F, Xue Y, et al. Development of an immun- ocytokine ,IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer. Gynecol Oncol, 2006, 103 : 848~852
33 Monk BJ, Choi DC, Pugnire G, et al. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol, 2005, 96 (3) : 902~905
2 Deshane J,Cabrera G,Grim J,etal.Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single chain antibody. Gynecol Oncol, 1995, 59 : 8~12
3 Al-Hendy A,Magliocco AM,Al-Tweigeri T,et al. Ovarian cancer gene therapy:repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. Am J Obstet Gynecol, 2000, 2(5) : 524~528
4 Kong B,Wang W,Liu C,et al. Efficacy of lentivirus- mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer. In Vivo, 2003, 17(2) : 153~156
5 Lu S, Wang X, Xiao L,et al. Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter. 2007, 6(3) : 397~404
6 Kigawa J , Terakawa N. Adenovirus-mediated transfer of a p53 gene in ovarian cancer. Adv Exp MedBiol, 2000, 465: 207~209
7 Song K, Cowan K H, Sinha B K. In vivo studies ofadenovirus-mediated p53 gene therapy for cisplatinum- resistant human ovarian tumor xenografts. Oncol Res, 1999, 11(3) : 153~ 156
8 Nielsen LL.Combination therapy with SCH58500(p53 adenovirus)and cyclophosphamide in predinical cancer models. Oncol Rep, 2000, 7(6) : 1191~1196
9 Buller RE,Shahin MS,Horowitz JA,et al.Long term follow-up of patints with recurrent ovarian cancer after Ad p53 gene replacement with SCH58500. Cancer Gene Ther, 2002, 9(7): 567~572
10 Yumi knegae1 Miho makimura and Izumu satio1 Asimple and efficient method for purfication of infections recombinant adenovirus. JPnJ Med Scibiol , 1994, 47 : 1571~1573
11 Vorburger SA ,Hunt KK1 Adenoviral gene therapy Oncol- ogist , 2002 ,1 :461
12 曹信杰,张颖,李会兰,等.重组人p53腺病毒注射液联合化疗治疗恶性体腔积液的疗效观察。中国药房, 2005, 23(16) : 1809~1810
13 Waston JM , Berek JS, M aza OM. Grow th inh ibition of ovarian cells induced by antisense IL-6 Oligonucleo tides. Gynecol Oncol, 1993, 49: 8
14 阮菲,解先宽,刘少阳,等. Survivin反义寡核苷酸对卵巢癌耐药细胞COC1/DDP抑制作用的实验研究。《癌症》, 2004, 23(8) : 896~899
15 Qian HN,L iu GZ, Cao SJ , et al. The experimental study ofovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes. Int J Gynecol Cancer, 2002, 12(1) : 80 ~ 85
16 Sterman DH,Gillespie CT,Carroll RG,et al. Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nat Clin Pract Oncol, 2006, 3(11) : 633~639
17 Sanches R ,Kuiper M,Penault-Llorca F,et al.Antitomoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer. implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy .Cancer Gene Ther, 2000, 7(5) : 707~720
18 Han X, Wilbanks GD, Devaja O, et al. IL-2 enhances- standard IFNgamma /LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy. Gynecol Oncol, 1999, 75 (2) : 198~ 210
19 Gyorffy S ,Palmer K,Pldor TJ , et al . Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL12. Immunol, 2001, 166(10) : 6212~6217
20 Mauceri H ,Seetharam S ,Beckett M, et al . Tumor produc- tion of angiostatin is enhanced after exposure to TNF-α. Int Cancer, 2002, 97(4) : 410~415
21 包大士等重组腺病毒载体介导血管抑素基因治疗大鼠脑胶质瘤的实验研究。中华神经科杂志, 2001, 17 (6) : 3670~3701
22 Brossart P , Wirt hs S , Stuhler G, et al. Induction of cytoto- xic T-lymphocyte responses in vivo after vaccinations with peptide pulsed dendritic cells. Blood , 2000, 96 : 3102~3108
23 Hernando JJ , Park TW, Kubler K, et al. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanc- ed gynaecological malignancies:clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother , 2002 , 51 : 45~52
24 Santin AD , Hermonat PL , Ravaggi A , et al . In vitro induction of tumor-specific human lymphocyte antigen class I rest rictedCD8 cytotoxic T lymphocytes by ovarian tumor antigen pulsed autologous dendritic cell s f rom patient swith advanced ovarian cancer . Am J Obstet Gynecol , 2000, 183 : 601~609
25 崔恒, 昌晓红, 冯捷, 等. 卵巢癌抗独特型单链抗体的人源化—抗独特型微抗体的构建与表达。中国生物化学与分子生物学报, 2002 , 18 : 490~494
26 Yang WL, Jie F , Chang XH, et al. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells. Gynecol Oncol, 2007,105 : 238~243
27 康玉,徐从剑,刘惜时,等. DC融合瘤苗治疗大鼠腹腔播散性卵巢癌。现代妇产科进展, 2005, 4(14) : 266~269
28 李芳,朱怀仕,贾平,等. 卵巢癌患者自体肿瘤细胞疫苗的临床应用。中华妇产科学杂志, 2004,1(39) : 51~52
29 Chen J , Cao ZY, Zhang P , et al. Study on the TIL and NKof IL-2 injected via pelvic retroperitoneal space in gynec- ological cancer patient. SiChuan University Transaction, 2004 , 35(3) : 406 ~408
30 Douglas D,Robert P, Catherine R,et al.Modulation of clinical reponse to IL-2 therapy in ovarian cancer patient.Gynecol Oncol , 2004, 94 : 54~60
31 王玉玲.TIL细胞联合IL-2腹腔注射治疗卵巢癌腹水12 例。山东医药,2002 ,42 (24) : 14
32 Zhang XY, Jie F, Xue Y, et al. Development of an immun- ocytokine ,IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer. Gynecol Oncol, 2006, 103 : 848~852
33 Monk BJ, Choi DC, Pugnire G, et al. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol, 2005, 96 (3) : 902~905